Starpoint

Starpoint Biosciences is a precision medicine company focused on the development and commercialization of non-invasive liquid biopsy diagnostics. The company utilizes its proprietary Electric Field-Induced Release and Measurement (EFIRM) technology to detect actionable mutations in bodily fluids, such as saliva and plasma, with high sensitivity and specificity. Its primary focus is on identifying Epidermal Growth Factor Receptor (EGFR) mutations in patients with non-small cell lung cancer (NSCLC) to guide targeted therapy. By providing a rapid and less invasive alternative to tissue biopsies, Starpoint Biosciences aims to improve patient outcomes through earlier detection and real-time monitoring of treatment response.